Millennium Management LLC Acquires New Holdings in VolitionRx Limited (NYSE:VNRX)

Millennium Management LLC purchased a new position in VolitionRx Limited (NYSE:VNRX) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 60,638 shares of the company’s stock, valued at approximately $36,000. Millennium Management LLC owned about 0.07% of VolitionRx at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Lagoda Investment Management L.P. grew its stake in shares of VolitionRx by 24.3% in the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after acquiring an additional 1,481,000 shares during the last quarter. Northern Trust Corp raised its holdings in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares in the last quarter. Finally, Two Sigma Securities LLC bought a new position in shares of VolitionRx during the fourth quarter valued at $29,000. Institutional investors own 8.09% of the company’s stock.

Insider Activity at VolitionRx

In other news, CEO Cameron John Reynolds purchased 181,818 shares of the company’s stock in a transaction on Wednesday, March 26th. The shares were purchased at an average cost of $0.55 per share, with a total value of $99,999.90. Following the completion of the transaction, the chief executive officer now owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. The trade was a 8.59% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders acquired 271,818 shares of company stock valued at $141,100. Corporate insiders own 10.40% of the company’s stock.

VolitionRx Stock Performance

NYSE VNRX opened at $0.64 on Friday. VolitionRx Limited has a 52 week low of $0.40 and a 52 week high of $0.90. The stock has a market capitalization of $65.50 million, a price-to-earnings ratio of -1.77 and a beta of 1.07. The stock’s 50 day moving average price is $0.50 and its two-hundred day moving average price is $0.57.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on VNRX shares. D. Boral Capital reiterated a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research note on Wednesday, April 30th. Jones Trading upgraded VolitionRx to a “strong-buy” rating and set a $3.00 price target on the stock in a research report on Tuesday, June 10th. Wall Street Zen began coverage on shares of VolitionRx in a report on Thursday, May 15th. They set a “sell” rating for the company. Finally, HC Wainwright began coverage on VolitionRx in a research note on Tuesday, April 8th. They issued a “buy” rating and a $2.50 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $3.50.

VolitionRx Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.